Trial Search Results

Trial of Aripiprazole in Trichotillomania

No medication has been reliably shown to benefit those suffering from trichotillomania (compulsive hair pulling). The current study proposes to evaluate the effectiveness of the medication aripiprazole for treatment of trichotillomania (TTM). Patients will take a gradually increased dose of the medication in an open-label study to see whether it relieves hair-pulling urges, decreases hair pulling behavior and is well tolerated.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: aripiprazole

Phase:

N/A

Eligibility


Inclusion Criteria:

Eligible patients:

   - Must be outpatients between the ages of 18 and 65 at the start of study

   - May be male or female

   - Have DSM-IV trichotillomania of at least 6 months duration

   - Allowed psychotropic medications are limited to:

      - SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine,
      sertraline), SNRIs (duloxetine, venlafaxine) and mirtazapine, as long as the
      dosage has not changed for 4 weeks prior to study enrollment.

      - Other allowed medications include non-hypnotic sleeping agents, specifically
      trazodone, diphenhydramine, hydoxyzine and ramelteon.

      - If a patient is taking non-allowed psychotropic medications, he/she must be
      titrated off by the prescribing physician and be off of the medication for at
      least 2 weeks prior to trial enrollment.

   - We will not exclude patients meeting DSM-IV criteria for:

      - body dysmorphic disorder;

      - major depression;

      - dysthymia;

      - GAD, social phobia, panic disorder.

Exclusion Criteria:

   - We will exclude patients suffering from:

      - organic mental disorders;

      - psychotic mental disorders including delusional disorder, somatic type;

      - mental retardation or developmental disabilities;

      - substance or alcohol abuse;

      - depressive disorders with current suicidal risk;

      - factitious disorders;

      - dissociative disorders;

      - obsessive compulsive disorder;

      - personality disorders sufficiently severe to interfere with cooperation with the
      study;

      - bipolar I or II disorder.

   - Patients taking psychotropic agents other than those specifically listed in item d
   above. If a patient is taking non-allowed psychotropic medications, he/she must be
   titrated off such medications by the prescribing physician and be off of the
   medication for 2 weeks prior to trial enrollment.

   - Pregnant or nursing women.

   - Patients with a known hypersensitivity or allergy to aripiprazole.

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Matthew White
6507255598
Not Recruiting